Eupraxia Pharmaceuticals Inc. (EPRX) dropped some encouraging news Thursday about its experimental treatment for eosinophilic esophagitis, a chronic inflammatory condition that makes swallowing difficult and painful. The company's ongoing RESOLVE trial is showing that EP-104GI doesn't just improve tissue health in the short term—it keeps working for months afterward.
The 12-week and 36-week data from the Phase 1b/2a portion of the trial paint a pretty clear picture. Patients getting the highest dose (8 mg per injection site) showed the most dramatic improvement at 12 weeks, with esophageal tissue approaching near-complete normalization. By 36 weeks, patients receiving the 4 mg/site dose maintained the tissue health gains they'd achieved at the 12-week mark.
Here's where it gets interesting. Among patients who had at least 60% of their esophagus treated with EP-104GI, 58% hit clinical remission at 12 weeks (19 patients). By 24 weeks, that jumped to 79% maintaining remission (14 patients). At the 52-week mark, 67% of six patients were still in remission.
The safety profile looks solid too. Across more than 200 patient-months of follow-up involving 31 patients, there haven't been any serious adverse events reported, and zero cases of oral candidiasis—a common complication with steroid treatments. The treatment has been well tolerated at all dose levels tested.
Back in September, Eupraxia first reported data from patients receiving the 8 mg dose in Cohort 9 of the trial's dose escalation portion.
Price Action: EPRX stock traded up 2.77% at $7.40 on Thursday.
